Cumberland Pharmaceuticals Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Cumberland Pharmaceuticals Inc. (CPIX) reported Revenue from Contract with Customer, Excluding Assessed Tax of $8.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-07
- Cumberland Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $8.80M, a 18.79% decline year-over-year.
- Cumberland Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $9.13M, a 22.04% decline year-over-year.
- Cumberland Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $13.68M, a 31.08% increase year-over-year.
- Cumberland Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $8.29M, a 8.73% decline year-over-year.
- Cumberland Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $44.52M, a 17.57% increase from fiscal 2024.
- Cumberland Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $37.87M, a 4.26% decline from fiscal 2023.
- Cumberland Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $39.55M, a 5.85% decline from fiscal 2022.
- Cumberland Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $42.01M, a 19.88% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $8.80M 10-Q · filed 2026-08-07 | $17.93M 10-Q · filed 2026-08-07 | $31.61M derived: sum of 3 quarters · filed 2026-08-07 | $39.90M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2026-03-31 | $9.13M 10-Q · filed 2026-05-08 | $22.81M derived: sum of 2 quarters · filed 2026-05-08 | $31.10M derived: sum of 3 quarters · filed 2026-05-08 | $41.94M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-12-31 | $13.68M 10-K · filed 2026-03-09 | $21.97M derived: sum of 2 quarters · filed 2026-03-09 | $32.81M derived: sum of 3 quarters · filed 2026-08-07 | $44.52M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $8.29M 10-K · filed 2026-03-09 | $19.13M derived: sum of 2 quarters · filed 2026-08-07 | $30.84M 10-Q · filed 2025-11-07 | $41.28M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-06-30 | $10.84M 10-Q · filed 2026-08-07 | $22.55M 10-Q · filed 2026-08-07 | $32.99M derived: sum of 3 quarters · filed 2026-08-07 | $42.07M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-03-31 | $11.71M 10-Q · filed 2026-05-08 | $22.15M derived: sum of 2 quarters · filed 2026-05-08 | $31.23M derived: sum of 3 quarters · filed 2026-05-08 | $41.08M derived: sum of 4 quarters · filed 2026-05-08 | ||||
| 2024-12-31 | $10.44M 10-K · filed 2026-03-09 | $19.52M derived: sum of 2 quarters · filed 2026-03-09 | $29.37M derived: sum of 3 quarters · filed 2026-03-09 | $37.87M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $9.09M 10-K · filed 2026-03-09 | $18.93M derived: sum of 2 quarters · filed 2026-03-09 | $27.43M 10-Q · filed 2025-11-07 | $36.79M derived: sum of 4 quarters · filed 2026-03-09 | ||||
| 2024-06-30 | $9.85M 10-K · filed 2026-03-09 | $18.35M 10-Q · filed 2025-08-08 | $27.70M derived: sum of 3 quarters · filed 2026-03-09 | $37.79M derived: sum of 4 quarters · filed 2026-03-09 | ||||
| 2024-03-31 | $8.50M 10-K · filed 2026-03-09 | $17.85M derived: sum of 2 quarters · filed 2026-03-09 | $27.94M derived: sum of 3 quarters · filed 2026-03-09 | $38.83M derived: sum of 4 quarters · filed 2026-03-09 | ||||
| 2023-12-31 | $9.35M 10-K · filed 2025-03-07 | $19.44M derived: sum of 2 quarters · filed 2025-03-07 | $30.33M derived: sum of 3 quarters · filed 2025-03-07 | $39.55M 10-K · filed 2025-03-07 | ||||
| 2023-09-30 | $10.09M 10-K · filed 2025-03-07 | $20.97M derived: sum of 2 quarters · filed 2025-03-07 | $30.20M 10-Q · filed 2024-11-08 | $39.32M derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2023-06-30 | $10.89M 10-K · filed 2025-03-07 | $20.11M 10-Q · filed 2024-08-09 | $29.24M derived: sum of 3 quarters · filed 2025-03-07 | $40.65M derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2023-03-31 | $9.22M 10-K · filed 2025-03-07 | $18.35M derived: sum of 2 quarters · filed 2025-03-07 | $29.76M derived: sum of 3 quarters · filed 2025-03-07 | $40.06M derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2022-12-31 | $9.12M 10-K · filed 2024-03-13 | $20.54M derived: sum of 2 quarters · filed 2024-03-13 | $30.84M derived: sum of 3 quarters · filed 2024-03-13 | $42.01M 10-K · filed 2024-03-13 | $40.68M 10-K · filed 2023-03-13 | |||
| 2022-09-30 | $11.41M 10-K · filed 2024-03-13 | $21.71M derived: sum of 2 quarters · filed 2024-03-13 | $32.89M 10-Q · filed 2023-11-13 | $40.27M derived: sum of 4 quarters · filed 2024-03-13 | ||||
| 2022-06-30 | $10.30M 10-K · filed 2024-03-13 | $21.47M 10-Q · filed 2023-08-11 | $28.85M derived: sum of 3 quarters · filed 2024-03-13 | $36.93M derived: sum of 4 quarters · filed 2024-03-13 | ||||
| 2022-03-31 | $11.18M 10-K · filed 2024-03-13 | $18.56M derived: sum of 2 quarters · filed 2024-03-13 | $26.63M derived: sum of 3 quarters · filed 2024-03-13 | $35.68M derived: sum of 4 quarters · filed 2024-03-13 | ||||
| 2021-12-31 | $7.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $15.45M derived: sum of 2 quarters · filed 2023-03-13 | $24.51M derived: sum of 3 quarters · filed 2023-03-13 | $35.05M 10-K · filed 2023-03-13 | ||||
| 2021-09-30 | $8.07M 10-Q · filed 2022-11-14 | $17.13M derived: sum of 2 quarters · filed 2022-11-14 | $27.67M 10-Q · filed 2022-11-14 | $36.33M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $9.06M 10-Q · filed 2022-08-12 | $19.59M 10-Q · filed 2022-08-12 | $28.25M derived: sum of 3 quarters · filed 2022-08-12 | $37.50M derived: sum of 4 quarters · filed 2022-08-12 | ||||
| 2021-03-31 | $10.54M 10-Q · filed 2022-05-13 | $19.20M derived: sum of 2 quarters · filed 2022-05-13 | $28.45M derived: sum of 3 quarters · filed 2022-05-13 | $38.05M derived: sum of 4 quarters · filed 2022-05-13 | ||||
| 2020-12-31 | $8.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $17.91M derived: sum of 2 quarters · filed 2022-03-11 | $27.51M derived: sum of 3 quarters · filed 2022-03-11 | $35.84M 10-K · filed 2022-03-11 | ||||
| 2020-09-30 | $9.25M 10-Q · filed 2021-11-12 | $18.85M derived: sum of 2 quarters · filed 2021-11-12 | $27.18M 10-Q · filed 2021-11-12 | $34.50M derived: sum of 4 quarters · filed 2022-03-11 | ||||
| 2020-06-30 | $9.60M 10-Q · filed 2021-08-13 | $17.93M 10-Q · filed 2021-08-13 | $25.25M derived: sum of 3 quarters · filed 2022-03-11 | $32.19M derived: sum of 4 quarters · filed 2022-03-11 | ||||
| 2020-03-31 | $8.33M 10-Q · filed 2021-05-14 | $15.66M derived: sum of 2 quarters · filed 2022-03-11 | $22.59M derived: sum of 3 quarters · filed 2022-03-11 | $32.01M derived: sum of 4 quarters · filed 2022-03-11 | ||||
| 2019-12-31 | $7.33M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $14.26M derived: sum of 2 quarters · filed 2022-03-11 | $23.68M derived: sum of 3 quarters · filed 2022-03-11 | $32.41M 10-K · filed 2022-03-11 | $45.55M 10-K · filed 2020-03-20 | |||
| 2019-09-30 | $6.94M 10-Q · filed 2020-11-13 | $10.37M 10-Q · filed 2019-11-13 | $16.35M derived: sum of 2 quarters · filed 2020-11-13 | $25.08M 10-Q · filed 2020-11-13 | $33.86M 10-Q · filed 2019-11-13 | $26.64M derived: sum of 4 quarters · filed 2021-03-12 | ||
| 2019-06-30 | $9.42M 10-Q · filed 2020-08-14 | $11.58M 10-Q · filed 2019-08-14 | $18.15M 10-Q · filed 2020-08-14 | $23.48M 10-Q · filed 2019-08-14 | $19.71M derived: sum of 3 quarters · filed 2021-03-12 | $28.20M derived: sum of 4 quarters · filed 2021-03-12 | ||
| 2019-03-31 | $8.73M 10-Q · filed 2020-05-22 | $11.90M 10-Q · filed 2019-05-15 | $10.29M derived: sum of 2 quarters · filed 2021-03-12 | $18.78M derived: sum of 3 quarters · filed 2021-03-12 | $28.95M derived: sum of 4 quarters · filed 2021-03-12 | |||
| 2018-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $10.05M derived: sum of 2 quarters · filed 2021-03-12 | $20.22M derived: sum of 3 quarters · filed 2021-03-12 | $28.80M 10-K · filed 2021-03-12 | $40.20M 10-K · filed 2019-03-12 | |||
| 2018-09-30 | $8.49M 10-Q · filed 2019-11-13 | $18.66M derived: sum of 2 quarters · filed 2019-11-13 | $27.24M 10-Q · filed 2019-11-13 | $23.29M derived: sum of 4 quarters · filed 2020-12-10 | ||||
| 2018-06-30 | $10.16M 10-Q · filed 2019-08-14 | $18.75M 10-Q · filed 2019-08-14 | $14.80M derived: sum of 3 quarters · filed 2020-12-10 | $26.00M derived: sum of 4 quarters · filed 2020-12-10 | ||||
| 2018-03-31 | $8.59M 10-Q · filed 2019-05-15 | $4.64M derived: sum of 2 quarters · filed 2020-12-10 | $15.83M derived: sum of 3 quarters · filed 2020-12-10 | |||||
| 2017-12-31 | -$3.95M derived: 8-K 12 month − 10-Q 9 month · filed 2020-12-10 | $7.25M derived: sum of 2 quarters · filed 2020-12-10 | $25.55M 8-K · filed 2020-12-10 | $40.38M 10-K · filed 2019-03-12 | ||||
| 2017-09-30 | $11.20M 10-Q · filed 2018-11-14 | $29.50M 10-Q · filed 2018-11-14 | ||||||
| 2016-12-31 | $32.48M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |